Actively Recruiting

Age: 18Years - 80Years
All Genders
ID05117424

The Impact of Cardiometabolic Factors on Coronary Artery and Cardiovascular Diseases: a Prospective Cohort Study

Led by Ruijin Hospital · Updated on 2024-08-06

3000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

The trial investigates the relationship between cardiometabolic factors and coronary artery diseases in patients with metabolic abnormalities such as diabetes, prediabetes, obesity, chronic kidney disease, and hyperuricemia. It is a prospective cohort study conducted at a single center, focusing on how these factors impact coronary disease progression and cardiovascular health over time. Participants with established coronary artery disease or metabolic disorders are enrolled and observed to assess changes in their coronary plaque and lesion severity over 12 months. Researchers also monitor cardiovascular events for up to five years to understand long-term outcomes linked to these metabolic conditions. During the study, participants undergo evaluations to measure coronary plaque progression and lesion severity, along with assessments of plaque characteristics. The study includes follow-up visits and monitoring to track cardiovascular events and disease progression. Participation spans from initial enrollment through at least one year for primary measurements and up to five years for secondary outcomes, providing a detailed understanding of disease development and risk factors.

CONDITIONS

Brief Title

CArdioMetabolism and Atherosclerotic PlaqUe progreSsion

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 80 years
  • Established coronary artery disease or metabolic disorders, including type 2 diabetes, prediabetes, obesity, chronic kidney disease, hyperuricemia, or dyslipidemia
  • Type 2 diabetes diagnosed by HbA1c 7 6.5%, fasting plasma glucose 7 7.0 mmol/l, 2h plasma glucose during OGTT 7 11.1 mmol/l, or receiving glucose-lowering agents
Not Eligible

You will not qualify if you...

  • Severe liver failure (Child-Pugh grade B to C)
  • Severe anemia (hemoglobin < 60g/L)
  • Familial hypercholesterolemia
  • Active malignant tumor
  • Active autoimmune diseases on corticosteroids
  • Acute or chronic infection
  • Life expectancy less than 1 year

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 5 years

Participants who undergo routine care are observed to assess coronary plaque progression and cardiovascular events.

Visits as part of routine healthcare

Trial Site Locations

Total: 1 location

1

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China, 200025

Actively Recruiting

Loading map...

Research Team

X

Xiaoqun Wang, M.D., Ph.D.

S

Shuo Feng, M.D.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Nutritional Approach for the Transformation and Reduction of...

Metabolic Syndrome

Actively Recruiting

1 location

The PILI 'Aina Project to Improve Cardiometabolic Health in...

Type 2 Diabetes

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here